Clinical Study to Assess the Efficacy and Safety of AT-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

Inclusion Criteria: * Subject has a clinical diagnosis of primary hyperhidrosis of the palms * Subject is currently drug-naïve for hyperhidrosis medications * Females must be post-menopausal, surgically sterile, or use an effective method of birth control Exclusion Criteria: * Subject is pregnant, lactating, is planning to become pregnant during the study, or is less than one year postpartum. * Subject is a user of nicotine products within one year prior to Visit 1/Screening. * Subject has known history of secondary hyperhidrosis. * Subject has existence of neurological, psychiatric, endocrine, or other disease that can cause secondary hyperhidrosis or affect sweating. * Subject has known history of Sjögren's syndrome or Sicca syndrome. * Subject has used any of the following hyperhidrosis medications or therapies within the specified timeframe: 1. Iontophoresis to the palms within four weeks prior to baseline visit; 2. Botulinum toxin to the palms within one year prior to baseline visit; 3. Prior surgical procedures to the palms (e.g., sympathectomy, debulking of sweat glands); 4. Prior medical device treatment to the palms (approved or investigational); 5. Any prescription treatments for hyperhidrosis within four weeks prior to baseline visit. 6. Any topical antiperspirant treatment to the palms within 7 days prior to baseline visit. * Subject is currently enrolled in an investigational drug or device study. * Subject has previously participated in a clinical study of dexmecamylamine or TC-5214. * Subject has used an investigational drug or investigational device treatment within 30 days prior to baseline.